Neurocrine Biosciences
NBIX
#1469
Rank
NZ$25.10 B
Marketcap
NZ$251.82
Share price
2.23%
Change (1 day)
5.09%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2025 (TTM): NZ$1.00 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are NZ$2.68 Billion. In 2024 the company made an earning of NZ$1.06 Billion, an increase over its 2023 earnings that were of NZ$0.54 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) NZ$1.00 B-5.7%
2024 NZ$1.06 B96.41%
2023 NZ$0.54 B41.13%
2022 NZ$0.38 B73.74%
2021 NZ$0.22 B-8.82%
2020 NZ$0.24 B77.78%
2019 NZ$0.13 B49.83%
2018 NZ$90.95 M-142.57%
2017 -NZ$0.22 Billion-14.73%
2016 -NZ$0.26 Billion53.15%
2015 -NZ$0.17 Billion46.25%
2014 -NZ$0.12 Billion29.66%
2013 -NZ$86.28 Million-3530.8%
2012 NZ$2.51 M-95.73%
2011 NZ$58.91 M
2009 -NZ$82.82 Million-45.38%
2008 -NZ$0.16 Billion-58.87%
2007 -NZ$0.37 Billion87.3%
2006 -NZ$0.2 Billion351.97%
2005 -NZ$43.55 Million-52.09%
2004 -NZ$90.89 Million-10.98%
2003 -NZ$0.11 Billion
2001 -NZ$76.21 Million
1999 -NZ$34.37 Million108.32%
1998 -NZ$16.5 Million
1996 NZ$5.03 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Repligen
RGEN
NZ$45.4 M-95.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$2.74 B 171.24%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
-NZ$8.33 Million-100.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$39.08 B 3,758.64%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$2.88 B 184.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$20.58 B 1,932.24%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$87.79 M-91.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-NZ$72.53 Million-107.16%๐Ÿ‡บ๐Ÿ‡ธ USA